{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-052291","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2021-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.747350+00:00","generated_at":"2026-06-28T21:39:49.918761+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Emmaus Life Sciences licenses IRAK4 inhibitor KM10544 from Kainos for cancer treatment","bullets":["Exclusive license for U.S., U.K., EU to Kainos' IRAK4 inhibitor KM10544 for cancers including leukemia, lymphoma, solid tumors.","Six-figure upfront cash payment; mid-eight-figure milestones; single-digit royalty on net sales; similar sublicensing fee.","Emmaus plans in-vivo studies, IND-enabling studies, and seeks Orphan Drug Designation.","Agreement expands existing R&D collaboration between Emmaus and Kainos."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-052291","json":"https://secwatch.observer/filing/0001213900-21-052291.json","markdown":"https://secwatch.observer/filing/0001213900-21-052291.md","text":"https://secwatch.observer/filing/0001213900-21-052291.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390021052291/0001213900-21-052291-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390021052291/ea148129-8k_emmanus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T21:39:49.918761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}